BACKGROUND: The molecular mechanism by which catecholaminergic polymorphic ventricular tachycardia is induced by single amino acid mutations within the cardiac ryanodine receptor (RyR2) remains elusive. In the present study, we investigated mutation-induced conformational defects of RyR2 using a knockin mouse model expressing the human catecholaminergic polymorphic ventricular tachycardia-associated RyR2 mutant (S2246L; serine to leucine mutation at the residue 2246). METHODS AND RESULTS: All knockin mice we examined produced ventricular tachycardia after exercise on a treadmill. cAMP-dependent increase in the frequency of Ca²⁺ sparks was more pronounced in saponin-permeabilized knockin cardiomyocytes than in wild-type cardiomyocytes. Site-directed fluorescent labeling and quartz microbalance assays of the specific binding of DP2246 (a peptide corresponding to the 2232 to 2266 region: the 2246 domain) showed that DP2246 binds with the K201-binding sequence of RyR2 (1741 to 2270). Introduction of S2246L mutation into the DP2246 increased the affinity of peptide binding. Fluorescence quench assays of interdomain interactions within RyR2 showed that tight interaction of the 2246 domain/K201-binding domain is coupled with domain unzipping of the N-terminal (1 to 600)/central (2000 to 2500) domain pair in an allosteric manner. Dantrolene corrected the mutation-caused domain unzipping of the domain switch and stopped the exercise-induced ventricular tachycardia. CONCLUSIONS: The catecholaminergic polymorphic ventricular tachycardia-linked mutation of RyR2, S2246L, causes an abnormally tight local subdomain-subdomain interaction within the central domain involving the mutation site, which induces defective interaction between the N-terminal and central domains. This results in an erroneous activation of Ca²⁺ channel in a diastolic state reflecting on the increased Ca²⁺ spark frequency, which then leads to lethal arrhythmia.
BACKGROUND: The molecular mechanism by which catecholaminergic polymorphic ventricular tachycardia is induced by single amino acid mutations within the cardiac ryanodine receptor (RyR2) remains elusive. In the present study, we investigated mutation-induced conformational defects of RyR2 using a knockin mouse model expressing the human catecholaminergic polymorphic ventricular tachycardia-associated RyR2 mutant (S2246L; serine to leucine mutation at the residue 2246). METHODS AND RESULTS: All knockin mice we examined produced ventricular tachycardia after exercise on a treadmill. cAMP-dependent increase in the frequency of Ca²⁺ sparks was more pronounced in saponin-permeabilized knockin cardiomyocytes than in wild-type cardiomyocytes. Site-directed fluorescent labeling and quartz microbalance assays of the specific binding of DP2246 (a peptide corresponding to the 2232 to 2266 region: the 2246 domain) showed that DP2246 binds with the K201-binding sequence of RyR2 (1741 to 2270). Introduction of S2246L mutation into the DP2246 increased the affinity of peptide binding. Fluorescence quench assays of interdomain interactions within RyR2 showed that tight interaction of the 2246 domain/K201-binding domain is coupled with domain unzipping of the N-terminal (1 to 600)/central (2000 to 2500) domain pair in an allosteric manner. Dantrolene corrected the mutation-caused domain unzipping of the domain switch and stopped the exercise-induced ventricular tachycardia. CONCLUSIONS: The catecholaminergic polymorphic ventricular tachycardia-linked mutation of RyR2, S2246L, causes an abnormally tight local subdomain-subdomain interaction within the central domain involving the mutation site, which induces defective interaction between the N-terminal and central domains. This results in an erroneous activation of Ca²⁺ channel in a diastolic state reflecting on the increased Ca²⁺ spark frequency, which then leads to lethal arrhythmia.
Authors: Christopher H George; Hala Jundi; Nicola Walters; N Lowri Thomas; Robert R West; F Anthony Lai Journal: Circ Res Date: 2005-12-08 Impact factor: 17.367
Authors: Prince J Kannankeril; Brett M Mitchell; Sanjeewa A Goonasekera; Mihail G Chelu; Wei Zhang; Subeena Sood; Debra L Kearney; Cristina I Danila; Mariella De Biasi; Xander H T Wehrens; Robia G Pautler; Dan M Roden; George E Taffet; Robert T Dirksen; Mark E Anderson; Susan L Hamilton Journal: Proc Natl Acad Sci U S A Date: 2006-07-27 Impact factor: 11.205
Authors: M Yano; K Ono; T Ohkusa; M Suetsugu; M Kohno; T Hisaoka; S Kobayashi; Y Hisamatsu; T Yamamoto; M Kohno; N Noguchi; S Takasawa; H Okamoto; M Matsuzaki Journal: Circulation Date: 2000-10-24 Impact factor: 29.690
Authors: Christopher H George; Hala Jundi; N Lowri Thomas; Mark Scoote; Nicola Walters; Alan J Williams; F Anthony Lai Journal: Mol Biol Cell Date: 2004-03-26 Impact factor: 4.138
Authors: Ye Win Oo; Nieves Gomez-Hurtado; Kafa Walweel; Dirk F van Helden; Mohammad S Imtiaz; Bjorn C Knollmann; Derek R Laver Journal: Mol Pharmacol Date: 2015-04-28 Impact factor: 4.436
Authors: Mette Nyegaard; Michael T Overgaard; Mads T Søndergaard; Marta Vranas; Elijah R Behr; Lasse L Hildebrandt; Jacob Lund; Paula L Hedley; A John Camm; Göran Wettrell; Inger Fosdal; Michael Christiansen; Anders D Børglum Journal: Am J Hum Genet Date: 2012-10-05 Impact factor: 11.025
Authors: Timothy L Domeier; Cale J Roberts; Anne K Gibson; Laurin M Hanft; Kerry S McDonald; Steven S Segal Journal: Am J Physiol Heart Circ Physiol Date: 2014-07-18 Impact factor: 4.733